Cargando…

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines, functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anand, Sai Priya, Prévost, Jérémie, Nayrac, Manon, Beaudoin-Bussières, Guillaume, Benlarbi, Mehdi, Gasser, Romain, Brassard, Nathalie, Laumaea, Annemarie, Gong, Shang Yu, Bourassa, Catherine, Brunet-Ratnasingham, Elsa, Medjahed, Halima, Gendron-Lepage, Gabrielle, Goyette, Guillaume, Gokool, Laurie, Morrisseau, Chantal, Bégin, Philippe, Martel-Laferrière, Valérie, Tremblay, Cécile, Richard, Jonathan, Bazin, Renée, Duerr, Ralf, Kaufmann, Daniel E., Finzi, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097665/ https://www.ncbi.nlm.nih.gov/pubmed/33969322 http://dx.doi.org/10.1016/j.xcrm.2021.100290

Ejemplares similares

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020)

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2021)

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
por: Tauzin, Alexandra, et al.
Publicado: (2021)

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2022)

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
por: Ding, Shilei, et al.
Publicado: (2020)

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection
por: Tauzin, Alexandra, et al.
Publicado: (2022)

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Chatterjee, Debashree, et al.
Publicado: (2022)

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
por: Tauzin, Alexandra, et al.
Publicado: (2023)

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2022)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
por: Boutin, Marianne, et al.
Publicado: (2022)

Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity
por: Marchitto, Lorie, et al.
Publicado: (2023)

Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2
por: Gong, Shang Yu, et al.
Publicado: (2022)

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity
por: Laumaea, Annemarie, et al.
Publicado: (2023)

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage
por: Boutin, Marianne, et al.
Publicado: (2023)

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
por: Chatterjee, Debashree, et al.
Publicado: (2022)

A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2023)

Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients
por: Tauzin, Alexandra, et al.
Publicado: (2022)

SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells
por: Ding, Shilei, et al.
Publicado: (2021)

An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
por: Nicolas, Alexandre, et al.
Publicado: (2022)

A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2021)

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality
por: Brunet-Ratnasingham, Elsa, et al.
Publicado: (2021)

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
por: Gasser, Romain, et al.
Publicado: (2021)

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4(+) T cell profile
por: Sannier, Gérémy, et al.
Publicado: (2023)

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
por: Prévost, Jérémie, et al.
Publicado: (2020)

Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
por: Gong, Shang Yu, et al.
Publicado: (2021)

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
por: Perreault, Josée, et al.
Publicado: (2020)

Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020)

The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
por: Ullah, Irfan, et al.
Publicado: (2022)

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay
por: Papenburg, Jesse, et al.
Publicado: (2021)

SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study
por: Lewin, Antoine, et al.
Publicado: (2021)

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
por: Marchitto, Lorie, et al.
Publicado: (2023)

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
por: Anand, Sai Priya, et al.
Publicado: (2020)

Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells
por: Richard, Jonathan, et al.
Publicado: (2021)

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
por: Ullah, Irfan, et al.
Publicado: (2021)

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2022)

Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir
por: Prévost, Jérémie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9apr15cujjgvidap2k4kseevi5